Your browser doesn't support javascript.
loading
Twelve-month outcomes of ranibizumab versus aflibercept for macular oedema in branch retinal vein occlusion: data from the FRB! registry.
Hunt, Adrian R; Nguyen, Vuong; Creuzot-Garcher, Catherine P; Alforja, Socorro; Gabrielle, Pierre-Henry; Zarranz-Ventura, Javier; Guillemin, Martin; Fraser-Bell, Samantha; Casaroli Marano, Ricardo P; Arnold, Jennifer; McAllister, Ian L; O'Toole, Louise; Gillies, Mark C; Barthelmes, Daniel; Mehta, Hemal.
Afiliación
  • Hunt AR; Medical Retina, Westmead Hospital, Westmead, New South Wales, Australia adrianhunt@eyesurgeonsmiranda.com.au.
  • Nguyen V; Save Sight Institute, University of Sydney, Sydney, New South Wales, Australia.
  • Creuzot-Garcher CP; Clinical Ophthalmology & Eye Health, The University of Sydney, Sydney, New South Wales, Australia.
  • Alforja S; Ophthalmology, Centre Hospitalier Universitaire de Dijon, Dijon, Bourgogne, France.
  • Gabrielle PH; Institut Clínic de Oftalmologia (ICOF), Hospital Clinic de Barcelona, Barcelona, Spain.
  • Zarranz-Ventura J; Ophthalmology, Centre Hospitalier Universitaire de Dijon, Dijon, Bourgogne, France.
  • Guillemin M; Eye and Nutrition Research Group, Centre des Sciences du Goût et de l'Alimentation, INRA Centre de Dijon, Dijon, Bourgogne, France.
  • Fraser-Bell S; Institut Clínic de Oftalmologia (ICOF), Hospital Clinic de Barcelona, Barcelona, Spain.
  • Casaroli Marano RP; Ophthalmology, Centre Hospitalier Universitaire de Dijon, Dijon, Bourgogne, France.
  • Arnold J; Clinical Ophthalmology & Eye Health, The University of Sydney, Sydney, New South Wales, Australia.
  • McAllister IL; Institut Clínic de Oftalmologia (ICOF), Hospital Clinic de Barcelona, Barcelona, Spain.
  • O'Toole L; Marsden Eys Specialists, Parramatta, Greater Western Sydney, Australia.
  • Gillies MC; Lions Eye Institute, The University of Western Australia, Nedlands, Western Australia, Australia.
  • Barthelmes D; The Mater Private Hospital, Dublin, Leinster, Ireland.
  • Mehta H; Save Sight Institute, University of Sydney, Sydney, New South Wales, Australia.
Br J Ophthalmol ; 106(8): 1178-1184, 2022 08.
Article en En | MEDLINE | ID: mdl-33712484
BACKGROUND/AIMS: To compare the efficacy of ranibizumab (0.5 mg) with aflibercept (2 mg) in the treatment of cystoid macular oedema due to branch retinal vein occlusion (BRVO) over 12 months. METHODS: A multicentre, international, database observational study recruited 322 eyes initiating therapy in real-world practice over 5 years. The main outcome measure was mean change in EDTRS letter scores of visual acuity (VA). Secondary outcomes included anatomic outcomes, percentage of eyes with VA >6/12 (70 letters), number of injections and visits, time to first inactivity, switching or non-completion. RESULTS: Generalised mixed effect models demonstrated that mean (95% CI) adjusted 12-month VA changes for ranibizumab and aflibercept were similar (+10.8 (8.2 to 13.4) vs +10.9 (8.3 to 13.5) letters, respectively, p=0.59). The mean adjusted change in central subfield thickness (CST) was greater for aflibercept than ranibizumab (-170 (-153 to -187) µm vs -147 (-130 to -164) µm, respectively, p=0.001). The overall median (Q1, Q3) of 7 (4, 8) injections and 9 (7, 11) visits was similar between treatment groups. First grading of inactivity occurred sooner with aflibercept (p=0.01). Switching was more common from ranibizumab (37 eyes, 23%) than from aflibercept (17 eyes, 11%; p=0.002). CONCLUSION: Visual outcomes at 12 months in this direct comparison of ranibizumab and aflibercept for BRVO in real-world practice were generally good and similar for the 2 drugs, despite a greater effect of aflibercept on CST and time to first grading of inactivity.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Proteínas Recombinantes de Fusión / Oclusión de la Vena Retiniana / Edema Macular / Inhibidores de la Angiogénesis / Receptores de Factores de Crecimiento Endotelial Vascular / Ranibizumab Tipo de estudio: Clinical_trials / Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies Límite: Humans Idioma: En Revista: Br J Ophthalmol Año: 2022 Tipo del documento: Article País de afiliación: Australia Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Proteínas Recombinantes de Fusión / Oclusión de la Vena Retiniana / Edema Macular / Inhibidores de la Angiogénesis / Receptores de Factores de Crecimiento Endotelial Vascular / Ranibizumab Tipo de estudio: Clinical_trials / Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies Límite: Humans Idioma: En Revista: Br J Ophthalmol Año: 2022 Tipo del documento: Article País de afiliación: Australia Pais de publicación: Reino Unido